More than half of new cancer drugs may not work, studies show

1. To stay healthy by eating, you must adhere to the formula "4 less, 4 more"
2. Does eating cold rice warm up to be dangerous to health?

A recent study of cancer drugs that appeared on the market found that there is a lot of evidence that they do not help enhance the treatment or maintain life for patients.

Researchers have found that cancer drugs are approved by the European Pharmaceutical Agency (EMA) in 2009 and 2013, with 57% (39/68 types) having evidence found to be unsuccessful. Maintaining or improving the quality of life of cancer patients after launch in the market.

After an average of five years of follow-up, only half of those who showed alive or increased quality of life thanks to anticancer drugs compared to current therapies.

According to the authors of King's College London and London School of Economics and Political Science (LSE): "The remaining 33% is uncertain about whether cancer drugs prolong survival or improve quality. Quality of life for cancer patients ".

Of the 23 drugs considered to be effective for patients with proven cancer, in fact only 11% of them are considered to have clinically significant benefit.

Author Huseyin Naci, assistant professor of LSE Ministry of Health, said: "It is very suspicious that very few cancer drugs have entered the European market without any clear evidence. about its important outcomes for patients and their treating physicians, related to cancer treatment as well as for survival and provides a better quality of life for patients. take measures to check and check materials and effectiveness of cancer drugs imported into the market ' .

Dr. Courtney Davis, a medical sociologist and politician from the Ministry of World Health and Social Affairs at King added: " We have evaluated the evidence base above for all New drugs entered the market in five years and found that the majority of them appeared on the market and found clear evidence that they did not or did little to improve survival for cancer patients or single patients. Maintaining and improving the quality of life ".

When it was discovered that the new drug was not enough evidence of effective cancer treatment, in some cases, the National Cancer Drug Fund should continue to gather more evidence before making a decision give up the last.

Speaking about the study, Emma Greenwood, director of UK cancer research, said: " This study does not necessarily show us what is happening in the UK. In Europe, national agencies. as Nice decides which drugs should be provided to patients and in the UK and should continue to accelerate this work. '

The author concludes, " Nice makes these decisions based on the clinical effectiveness and cost of a drug to determine what value it will bring to cancer patients ."

This research has just been published in the British Journal of Medicine.